Combining a TriVax vaccine, containing the gp100 TAA, Poly-IC, and anti-CD40 mAb, with another IL-2/anti-IL-2 complex (IL-2/JES6-5H4), with selectivity toward the intermediate-affinity IL-2R, supported enhanced expansion of gp100-specific adoptively transferred Pmel-1 T cells and anti-tumor responses when compared to TriVax monotherapy. This evidence concerns the gene PMEL and neoplasm.